TRUEX PAUL F
Known title: DirectorCIK: 0001120362
TRUEX PAUL F's purchase track record
TRUEX PAUL F has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/31/2022 | MIST | $28K | +51.7% | -12.3% | -4.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MIST | ▲ Buy | Option Exercise | 8,016 | $9K | 5/31/2022 | View on chart |
| MIST | ▲ Buy | Option Exercise | 45,072 | $69K | 5/31/2022 | View on chart |
| MIST | ▲ Buy | Option Exercise | 22,870 | $35K | 5/31/2022 | View on chart |
| MIST | ▲ Buy | Option Exercise | 822 | $2K | 5/31/2022 | View on chart |
| MIST | ▲ Buy | Open Market | 5,000 | $28K | 5/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial
Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.